Category: Redefining Every Stage Investments (RESI)

The Redefining Every Stage Investments (RESI) Conference is an ongoing conference series that provides an international venue for life science companies across Biotech, Medtech, Diagnostics and Healthcare IT and to source investors from around the globe, create relationships, and eventually, secure funding.

Top 10 Challenges for Startups Raising Capital and Seeking Licensing Deals

~ Next Phase Admin ~ Leave a comment

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the LSN Partnering Conference Series

Check out a recent list of the top challenges startups face when entering the early-stage fundraising arena. Each challenge is linked to an article tackling these and similar issues.

  1. Migrating from regional mindset to global partnering arena
  2. Understanding that deals take 9-18 months and identifying vehicles that can assist in partnering campaigns early
  3. Defining and understanding their competitive landscape
  4. Compiling a global target list (GTL) that is a fit for product and stage of development
  5. Understanding the cost of launching and executing a global partnering campaign ($60K-$90K)
  6. Developing branding and messaging that highlights unique company value that is clear, concise, and easy to understand
  7. Implementing a CRM to activate and organize global campaign, which includes ongoing curation of partner list, outreach initiatives, and tracks status and to-do list for all meetings
  8. Hitting the road with phone and email canvassing, as well as traveling to conferences to engage partners
  9. Learning the art of follow-up (99% of all startups fail here)
  10. Learning how to efficiently partner at a partnering conference

Life Science Nation is committed to facilitating well-fitting meetings between founders with innovative assets and the capital and channel partners who seek them. Join us for one of our free fundraising bootcamps to learn about the products and services we offer to the startup community in life science and healthcare.

Preparing to Pitch at RESI 
  • Alexander Vassallo, Manager, Business Development, Life Science Nation
The Innovator’s Pitch Challenge (IPC) is an opportunity for early-stage companies to gain additional exposure to conference attendees, pitch directly to a panel of relevant investors, and participate in a live Q&A session. This bootcamp will walk through the process of preparing your pitch materials and what to expect in a live pitch session, including frequently asked questions from investor judges.

Fundraising 101: Avoiding Pitfalls and Improving the Odds
  • Karen Deyo, Director, Investor Research, Israel Business Development, Life Science Nation
  • Candice He, Vice President, Business Development, Global Investment Strategist, Life Science Nation
This bootcamp is designed to help scientist-entrepreneurs navigate the world of fundraising. It starts out by debunking some commonly held misconceptions about early-stage startups and fundraising, followed by tips on how to improve your chances and increasing investor visibility.
Preparing to Pitch at RESI
  • Candice He, Vice President, Business Development, Global Investment Strategist, Life Science Nation
The Innovator’s Pitch Challenge (IPC) is an opportunity for early-stage companies to gain additional exposure to conference attendees, pitch directly to a panel of relevant investors, and participate in a live Q&A session. This bootcamp will walk through the process of preparing your pitch materials and what to expect in a live pitch session, including frequently asked questions from investor judges.
Strategies for Successful Partnering
  • Alexander Vassallo, Manager, Business Development, Life Science Nation
  • Joey Wong, Analyst, Investor Research, Hong Kong BD Life Science Nation
This bootcamp is a fan favorite with tried-and-true tips to make your partnering experience exceptional, letting your technology, product, and team take center-stage. Whether booking 1-on-1 meetings or pitching to a panel, these strategies will help you prioritize the details that make a difference in telling your story to potential investors and strategic partners.

Our Redefining Early Stage Investments (RESI) conference returns in a virtual format June 7-9. Register today and save $300 on super early bird rates by April 15!

Register-now-button-new

Hot Longevity Mandate: East Coast Based VC Fund

~ Next Phase Admin ~ Leave a comment

The firm is a New York based early-stage fund founded in 2019. The firm is affiliated with, but separate from, a New York based university, leveraging the network of schools and 70,000 + alumni network to

help their portfolio companies. The firm invests in technology-based companies in the pre-seed and seed stage, and while they prefer the companies have some revenue, they will invest in pre-revenue companies. The firm invests in several verticals, including Seniors and Tech, PropTech, Fintech, Cybersecurity, HealthTech and AI/ML. The firm does not invest in therapeutics or medical devices. The firm invests in North America and in Israel, with check size between $50-150K into rounds with a pre-money valuation of $2-10M.

Within HealthTech, the firm invests in Seniors and Tech and digital health. For digital health, the company is interested primarily in B2B models, but will invest in B2B2C as well. The firm has a special interest in Agetech, as one of the GPs is third generation senior living owner/operator.

The firm does not lead rounds, but is a very active investor alongside top-tier funds. Due to their strategic value, they are asked to serve in an advisory capacity. The firm prides itself on being a valued strategic partner. The firm will invest in new or seasoned entrepreneurs, who have assembled exceptional teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Hot Longevity Mandate: West Coast Based VC Fund

~ Next Phase Admin ~ Leave a comment

The firm is based in San Francisco, CA, and has an additional office in Japan. The firm is investing from a new fund that closed in 2016. The firm generally invests in Series A equity rounds, and typically commits a total of $1-4 million over the course of an investment. The firm invests 70% of its capital in the USA and Israel, with the remaining 30% in Japan. Under certain circumstances, the firm will invest outside those regions.

The firm invests in advanced therapeutics, healthcare IT, novel (sensor based IoT) devices and diagnostics, and second generation tools and technologies in the biotech R&D/laboratory innovation field. The firm is open to any indication area, and has a particular interest in diseases that afflict the elderly including Alzheimer’s disease and cancer. The firm prefers to invest in technologies at an early stage of development.

The firm is interested in working with high quality management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Hot Longevity Mandate: UK-Based Family Office

~ Next Phase Admin ~ Leave a comment

The firm is an active early stage venture fund based in the UK and Switzerland. The team is composed of experienced professionals in funding, entrepreneurship and therapeutic development. The firm has historically invested in computational biology, next generation tools for protein analysis and cell and gene therapy manufacturing technologies. Majority of technologies in the firm’s portfolio are relating to oncology, but going ahead the firm will consider any indication, if they find technology compelling. Firm has invested primarily in the UK and is willing to consider companies based in the broader Europe and in Switzerland in particular.

The firm is especially interested in companies developing therapeutic approaches, such as state of the art cell therapies that need local manufacturing, cancer vaccines, precision oncology medicine and novel therapies for autoimmune diseases. Delin Ventures is primarily interested in early stage, pre-clinical breakthrough technologies seeking seed investment.

The firm takes an active role with the companies in which they invest. The firm frequently leads rounds, and supports and mentors the early stage companies, often either taking a board seat themselves or finding an expert to serve on the board. Apart of building companies, the firm is also interested in the investment in the existing companies, syndicating with other investors

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Top 10 Challenges for Startups Raising Capital and Seeking Licensing Deals

~ Next Phase Admin ~ Leave a comment

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the LSN Partnering Conference Series

Check out a recent list of the top challenges startups face when entering the early-stage fundraising arena. Each challenge is linked to an article tackling these and similar issues.

  1. Migrating from regional mindset to global partnering arena
  2. Understanding that deals take 9-18 months and identifying vehicles that can assist in partnering campaigns early
  3. Defining and understanding their competitive landscape
  4. Compiling a global target list (GTL) that is a fit for product and stage of development
  5. Understanding the cost of launching and executing a global partnering campaign ($60K-$90K)
  6. Developing branding and messaging that highlights unique company value that is clear, concise, and easy to understand
  7. Implementing a CRM to activate and organize global campaign, which includes ongoing curation of partner list, outreach initiatives, and tracks status and to-do list for all meetings
  8. Hitting the road with phone and email canvassing, as well as traveling to conferences to engage partners
  9. Learning the art of follow-up (99% of all startups fail here)
  10. Learning how to efficiently partner at a partnering conference

Life Science Nation is committed to facilitating well-fitting meetings between founders with innovative assets and the capital and channel partners who seek them. Our Redefining Early Stage Investments (RESI) conference returns in a virtual format June 7-9. Register today and save $300 on super early bird rates by April 15!

Digital RESI March IPC Winners

~ Next Phase Admin ~ Leave a comment

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

Another Digital Redefining Early Stage Investments (RESI) conference is in the books! At Digital RESI March, nearly 40 life science and healthcare startups participated in the Innovator’s Pitch Challenge (IPC), a unique pitching opportunity for early-stage companies in therapeutics, medical device, diagnostics, digital health, and R&D/services sectors.

The IPC has a voting component on which all registered attendees – from fellow startup executives to active early-stage investors – can vote for their favorite companies based on the materials displayed on their dedicated landing pages (pitch video, slide deck, executive summary, etc.) as well as their performance in live Q&A sessions, in which founders pitch directly to and participate in a subsequent Q&A with investor judges.

Life Science Nation is pleased to share the winners of last week’s IPC who received the most votes during the 3-day conference. Congratulations to the winners! Check them out below and see the full list of finalists. The IPC returns June 7-9 and applications are open! Apply today and save $300 by April 15!

Embrace Prevention Care (1st Place)

Embrace is a leader in geriatric preventive care, providing an integrated suite of telehealth, pharmacy and behavioral change services to improve health and reduce costs. We help older adults with chronic conditions take meaningful actions to reduce hospitalizations and extend safe aging in place. Our local nurse practitioners partner with physicians to help their patients implement care plans and follow medication regimens, creating new practice revenue and reducing the complex patient burden.

Bold Therapeutics (2nd Place)

Bold Therapeutics Inc. is a clinical-stage oncology company founded in 2018 by a team of biopharma industry veterans to develop and commercialize BOLD-100, a first-in-class anti-resistance therapeutic. BOLD-100 significantly enhances the activity of a wide range of other anti-cancer therapies by disabling a critical and previously untargeted cancer resistance, survival and proliferation pathway. Based on compelling preclinical and early clinical results, Bold Therapeutics is focusing its development efforts on some of the most challenging cancer indications where existing therapies are largely ineffective, resulting in a significant unmet medical need.

CoolSpine (3rd Place)

CoolSpine LLC was spun out of Yale University and is developing two neuroprotective medical devices that induce localized hypothermia to address injuries from spinal or cerebral ischemia. The patented devices cool the Cerebrospinal fluid in either the brain or the spinal cord to levels known to be neuroprotective (32°-35º C). By using the CSF to induce hypothermia, the devices uniquely cool the targeted areas while maintaining systemic normothermia, a significant benefit that avoids the complications of systemic hypothermia. The devices are incorporated into ventricular or intrathecal catheters, standard products for brain or spinal protection and therefore require no additional invasive intervention. CoolSpine’s primary targets are spinal cord and cerebral ischemia.

National Institute on Aging Launches Startup Challenge

~ Next Phase Admin ~ Leave a comment

By Candice He, Vice President of Business Development, Global Investment Strategist, LSN

CH_new

Life Science Nation is pleased to share an exciting opportunity for the longevity and age-tech startup community: The National Institute on Aging is hosting a startup challenge, The Healthy Aging Start-Up Challenge and Bootcamp to Foster Diversity and Accelerate Innovation, and applications are open! Apply by May 23 to win a cash prize, one-on-one mentoring, and access to an entrepreneur bootcamp!

NIAstartupchallengeAd

Apply-here

About the Challenge

The Healthy Aging Start-Up Challenge and Bootcamp to Foster Diversity and Accelerate Innovation invites applications from diverse researchers and entrepreneurs with a demonstrated need for entrepreneurial resources. Applicants should have innovative ideas for science-driven technologies and products that aim to promote healthy aging or address aging-related diseases or conditions, including Alzheimer’s disease and related dementias. There is special interest in participants and ideas that have the potential to increase the diversity of NIA-funded small business research and development. NIA strongly encourages applications from researchers and entrepreneurs from groups underrepresented in the U.S. biomedical sciences and in life science entrepreneurship.

Up to 20 finalists will be selected to participate in a 4-month entrepreneurial bootcamp designed to provide resources to help overcome barriers to launching a start-up and obtaining funding. The bootcamp will include entrepreneur workshops, mentorship, networking opportunities, and grant application skill building. Participation will be mostly virtual and will require finalists to commit approx. 4-6 hours per week plus one 3-to 4-day in-person networking event scheduled for September 19-22, 2022 in Boston (travel expenses paid by NIA). At the conclusion of the bootcamp, finalists will pitch to be selected as one of up to five winners to each receive a $60,000 cash prize. 

Applicants are encouraged to attend the Pre-Application Webinar scheduled for April 20, 2022, at 2 PM ET to learn more about the Challenge.

register-now-blue

Calling for Mentors

Mentorship is a critical component of this program. As participants will be learning to refine their idea, develop a pitch deck, identify markets and investors, and launch a new life science venture, the NIA is seeking volunteer mentors with an interest in diversity who are passionate about sharing their expertise in areas like entrepreneurship, investing, product development, digital health, and/or science and technology related to aging and Alzheimer’s disease. Mentoring relationships with individuals of shared backgrounds and experiences are especially beneficial to mentee success, so the NIA is especially excited to recruit mentors with unique or underrepresented backgrounds. Please share the link below for mentors with anyone who you feel may be a good fit.

Mentor applications are due May 2, so apply today!

apply-to-mentor